{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:57:04Z","timestamp":1791493024261,"version":"4.3.4"},"reference-count":24,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.3892\/ol.2016.4259","type":"journal-article","created":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T09:34:07Z","timestamp":1456220047000},"page":"2347-2352","source":"Crossref","is-referenced-by-count":12,"title":["Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes"],"prefix":"10.3892","volume":"11","author":[{"given":"KAI","family":"DING","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RONG","family":"FU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HUI","family":"LIU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DEEPAK ANIL","family":"NACHNANI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZONG-HONG","family":"SHAO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2016,2,23]]},"reference":[{"key":"key20180108094517_b1-ol-0-0-4259","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0145-2126(02)00098-X","article-title":"The myelodysplastic syndrome(s): A perspective and review highlighting current controversies","volume":"27","author":"Steensma","year":"2003","journal-title":"Leuk Res"},{"key":"key20180108094517_b2-ol-0-0-4259","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/cncr.22602","article-title":"The incidence and impact of thrombocytopenia in myelodysplastic syndromes","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Cancer"},{"key":"key20180108094517_b3-ol-0-0-4259","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/10428199909083382","article-title":"Risks, costs and alternatives to platelet transfusion","volume":"34","author":"Webb","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"key20180108094517_b4-ol-0-0-4259","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa041668","article-title":"Efficacy of lenalidomide in myelodysplastic syndromes","volume":"352","author":"List","year":"2005","journal-title":"N Engl J Med"},{"key":"key20180108094517_b5-ol-0-0-4259","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/bjc.1991.258","article-title":"The antileukemic activity of 5-aza-2-deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia","volume":"64","author":"Richel","year":"1991","journal-title":"Br J Cancer"},{"key":"key20180108094517_b6-ol-0-0-4259","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-2141.2001.02933.x","article-title":"Cytogenetic responses in high-risk myelodysplastic syndromes following low-dose treatment with the DNA methylation inhibitor 5-aza-2-deoxycytidine","volume":"114","author":"L\u00fcbbert","year":"2001","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"key20180108094517_b7-ol-0-0-4259","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s00277-005-0008-x","article-title":"Decitabine: A historical review of the development of an epigenetic drug","volume":"84","author":"de Vos","year":"2005","journal-title":"Ann Hematol"},{"key":"key20180108094517_b8-ol-0-0-4259","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1517\/13543784.12.12.1985","article-title":"DNA methylation in haematological malignancies: The role of decitabine","volume":"12","author":"Hennessy","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"key":"key20180108094517_b9-ol-0-0-4259","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1160\/TH10-11-0744","article-title":"The effect of decitabine on megakaryocyte maturation and platelet release","volume":"106","author":"Wang","year":"2011","journal-title":"Thromb Haemost"},{"key":"key20180108094517_b10-ol-0-0-4259","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.leu.2400526","article-title":"Continous infusion of low dose 5-aza-2\u2032-deoxycytidine in elderly patients with high-risk myelodysplastic syndromes","volume":"11","author":"Wijermans","year":"1997","journal-title":"Leukemia"},{"key":"key20180108094517_b11-ol-0-0-4259","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.2000.18.5.956","article-title":"Low dose 5-aza-2\u2032-deoxycytidine, a DNA-hypomethylating agent for the treatment of high-risk myelodysplastic syndromes: A multicenter phase II study in elderly patients","volume":"18","author":"Wijermans","year":"2000","journal-title":"J Clin Oncol"},{"key":"key20180108094517_b12-ol-0-0-4259","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.leukres.2003.11.016","article-title":"The effects of 5-aza-2\u2032-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes","volume":"28","author":"Van den Bosch","year":"2004","journal-title":"Leuk Res"},{"key":"key20180108094517_b13-ol-0-0-4259","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00277-011-1186-3","article-title":"Staurosporine induces megakaryocytic differentiation through the upregulation of JAK\/Stat3 signaling pathway","volume":"90","author":"Peng","year":"2011","journal-title":"Ann Hematol"},{"key":"key20180108094517_b14-ol-0-0-4259","first-page":"88","article-title":"Myelodysplastic syndromes","author":"Brunning","year":"2008","journal-title":"World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissue"},{"key":"key20180108094517_b15-ol-0-0-4259","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia: Revised recommendations of the International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20180108094517_b16-ol-0-0-4259","doi-asserted-by":"crossref","first-page":"30","DOI":"10.6004\/jnccn.2011.0005","article-title":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic syndromes","volume":"9","author":"Greenberg","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"key20180108094517_b17-ol-0-0-4259","doi-asserted-by":"crossref","DOI":"10.1111\/ijlh.12408","article-title":"Leishman and Giemsa stain: A new reliable staining technique for blood\/bone marrow smears","author":"Gajendra","year":"2015","journal-title":"Int J Lab Hematol"},{"key":"key20180108094517_b18-ol-0-0-4259","first-page":"1347","article-title":"Morphological analysis of the megakaryocytes in myelodysplastic syndrome","volume":"38","author":"Mori","year":"1990","journal-title":"Rinsho Byori"},{"issue":"Suppl 1","key":"key20180108094517_b19-ol-0-0-4259","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1538-7836.2009.03398.x","article-title":"Regulation of megakaryocyte maturation and platelet formation","volume":"7","author":"Bluteau","year":"2009","journal-title":"J Thromb Haemost"},{"key":"key20180108094517_b20-ol-0-0-4259","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.3390\/molecules19045448","article-title":"Two ellagic acids isolated from roots of sanguisorba officinalis L. Promote hematopoietic progenitor cell proliferation and megakaryocyte differentiation","volume":"19","author":"Gao","year":"2014","journal-title":"Molecules"},{"key":"key20180108094517_b21-ol-0-0-4259","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-013-1863-5","article-title":"Lenalidomide as a disease-modifying agent in patients with del (5q) myelodysplastic syndromes: Linking mechanism of action to clinical outcomes","volume":"93","author":"Giagounidis","year":"2014","journal-title":"Ann Hematol"},{"key":"key20180108094517_b22-ol-0-0-4259","first-page":"1","article-title":"Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS) and their distinction from low risk MDS","volume":"36","author":"Valent","year":"2012","journal-title":"Leuk Res"},{"key":"key20180108094517_b23-ol-0-0-4259","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/00001813-199704000-00008","article-title":"Pilot phase I\u2013II study on 5-aza-2-deoxycytidine (Decitabine) in patients with metastatic lung cancer","volume":"8","author":"Momparler","year":"1997","journal-title":"Anticancer Drugs"},{"key":"key20180108094517_b24-ol-0-0-4259","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1182\/blood.V96.7.2379","article-title":"5-Aza-2-deoxycytidine and foetal haemoglobin induction in sickle cell anaemia","volume":"96","author":"Koshy","year":"2000","journal-title":"Blood"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2016.4259\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T23:54:07Z","timestamp":1600214047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2016.4259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,23]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,2,23]]},"published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.3892\/ol.2016.4259"],"URL":"https:\/\/doi.org\/10.3892\/ol.2016.4259","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,23]]}}}